Literature DB >> 20224513

Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation.

Nicholas Duncan1, Julie Arrazi, Sandeep Nagra, Mark Cook, Alison H Thomson, Charles Craddock.   

Abstract

Currently, routine monitoring of cyclosporine in patients undergoing allogeneic stem cell transplantation is based on analysis of trough, or C0, predose concentrations. However, recent studies in solid organ transplant recipients have demonstrated that monitoring cyclosporine exposure by analyzing 2-hour postdose concentrations (C2) or area under the concentration-time curve (AUC) may improve clinical outcome. This study investigated the ability of single samples to predict exposure to intravenous cyclosporine in eight patients undergoing allogeneic stem cell transplantation. Patients received cyclosporine at a starting dose of 2.5 mg/kg 12-hourly by intravenous infusion over 4 hours. Blood samples were taken at 0, 1, 2, 3, 4, 4.17, 4.33, 4.67, 5, 6, 8, and 12 hours after the start of the infusion. Linear regression was undertaken to investigate the relationship between AUC and concentrations measured at individual time points; bias and precision were also examined. Cyclosporine doses ranged from 250 mg to 430 mg/day, AUC from 3.85 to 8.39 mg.h/L, clearance from 19.1 to 48.1 L/h, and elimination half-life from 3.7 to 15.5 hours. Although Cmax and the concentration measured at 3 hours (C3) provided the best prediction of AUC (r = 0.90 and r = 0.87, respectively), the infusion protocol made the time of Cmax difficult to predict. Concentrations measured at the end of the infusion (Cend) and 12 hours postdose (C12) gave similar results (r = 0.87 and 0.77, respectively). These data suggest that C12 concentrations provide an acceptable marker of total exposure to intravenous cyclosporine in patients undergoing allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224513     DOI: 10.1097/FTD.0b013e3181d5881f

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.

Authors:  Patrick Medd; Ian Monk; Robert Danby; Ram Malladi; Ruth Clifford; Amanda Ellis; David Roberts; Chris Hatton; Paresh Vyas; Tim Littlewood; Andy Peniket
Journal:  Int J Hematol       Date:  2011-09-07       Impact factor: 2.490

2.  Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010.

Authors:  Takatoshi Kokuhu; Keizo Fukushima; Hidetaka Ushigome; Norio Yoshimura; Nobuyuki Sugioka
Journal:  Int J Med Sci       Date:  2013-09-23       Impact factor: 3.738

3.  Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.

Authors:  Irene García Cadenas; David Valcarcel; Rodrigo Martino; J L Piñana; Pere Barba; Silvana Novelli; Albert Esquirol; Ana Garrido; Silvana Saavedra; Miquel Granell; Carol Moreno; Javier Briones; Salut Brunet; Jorge Sierra
Journal:  Mediators Inflamm       Date:  2014-01-30       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.